Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
27.28
-2.34 (-7.90%)
Mar 31, 2025, 9:47 AM EDT - Market open

Company Description

Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.

It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis.

The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, which are in Phase I and IND-enabling respectively.

The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics, Inc.
Kymera Therapeutics logo
Country United States
Founded 2015
IPO Date Aug 21, 2020
Industry Biotechnology
Sector Healthcare
Employees 188
CEO Nello Mainolfi

Contact Details

Address:
200 Arsenal Yards Boulevard, Suite 230
Watertown, Massachusetts 02472
United States
Phone 857 285 5300
Website kymeratx.com

Stock Details

Ticker Symbol KYMR
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001815442
CUSIP Number 501575104
ISIN Number US5015751044
Employer ID 81-2992166
SIC Code 2836

Key Executives

Name Position
Dr. Nello Mainolfi M.D., Ph.D. Co-Founder, President, Chief Executive Officer and Director
Dr. Bruce L. Booth DPHIL, Ph.D. Co-Founder and Independent Chairman
Bruce N. Jacobs CFA Chief Financial Officer
Dr. Jeremy G. Chadwick Ph.D. Chief Operating Officer
Ellen V. Chiniara Esq., J.D. Chief Legal Officer and Corporate Secretary
Dr. Jared A. Gollob M.D. Chief Medical Officer
Justine E. Koenigsberg Vice President of Investor Relations
Karen Weisbach Head of People and Culture
Dr. Juliet Williams B.A Ph.D. Head of Research

Latest SEC Filings

Date Type Title
Mar 3, 2025 144 Filing
Mar 3, 2025 144 Filing
Mar 3, 2025 144 Filing
Mar 3, 2025 144 Filing
Mar 3, 2025 8-K Current Report
Feb 27, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 10, 2025 SCHEDULE 13G/A Filing
Jan 14, 2025 8-K Current Report